stockrowCelularity, Inc.
CELU Healthcare Biotechnology
Celularity, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $26.6 million, down 51.0% from fiscal 2024.
- Revenue
- −5.30%
- EPS
- +102.0%
- Free cash flow
- −10.9%
- Total debt
- −1.51%
Quarter to June 2026, against a year earlier
Follow CELU
Alert me
Celularity, Inc. (CELU) EV/Sales
As of 6 November 2026, Celularity, Inc. (CELU) trades at a EV/Sales of 3.4×. Over the past ten years it has ranged from 0.0× (June 2021) to 67.8× (April 2022); the current reading is higher than 53% of that period. That is below the Biotechnology industry median of 9.0× and in line with the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.6× | 64.29% |
| FY2024 | 1.6× | (68.19%) |
| FY2023 | 5.0× | (56.73%) |
| FY2022 | 11.7× | (26.19%) |
| FY2021 | 15.8× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.2× | (23.56%) |
| Mar 2026 | 4.2× | 58.62% |
| Dec 2025 | 2.6× | 13.45% |
| Sep 2025 | 2.3× | 15.68% |
| 20 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RNAZ TransCode Therapeutics Inc. compare | n/m |
| AARD Aardvark Therapeutics, Inc. compare | n/m |
| FLNA Cassava Sciences, Inc. compare | n/m |
| NXTC NextCure, Inc. compare | 0.4× |
| CRVO CervoMed Inc. compare | 0.6× |
| EVAX Evaxion A/S - Sponsored ADR compare | 1.4× |
| CELU Celularity, Inc. | 3.4× |
| IGC IGC Pharma, Inc. compare | 19.3× |
| CVM Cel-Sci Corporation compare | 27.6× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)